Artizan and Cybrexa complete financing rounds

Yale spinout Artizan Biosciences, a New Haven biotech focused on curing inflammatory bowel disease, has raised $11 million in a financing round that includes an investment from New Haven’s Biohaven Pharmaceuticalsmore

Cybrexa Therapeutics, an oncology-focused biotechnology company, has completed a $25 million Series B financing … more